Fuan pharmaceutical's class 3.1 new high blood pressure drug, Nabil hydrochloride, will enter the field for examination and impact the first imitation in China

According to the public information, Nabil hydrochloride is the third generation beta blocker developed by Johnson & Johnson, which is used to treat primary hypertension and mild to moderate stable chronic heart failure According to the Research Report of Guolian securities, in 2012, the global sales of Nabil hydrochloride reached US $1 billion, which is also a potential 1 billion product in the domestic market CFDA website information shows that at present, only Fuan pharmaceutical and Jiangxi Qingfeng pharmaceutical have declared the production of the product Among them, Qingfeng pharmaceutical products are still in the drug evaluation center to carry out pharmacotoxicology, clinical and pharmaceutical evaluation, and the progress lags behind Fuan pharmaceutical Fu'an pharmaceutical is mainly engaged in the production and sales of antibiotics, and is actively transforming to specialized drugs Nabil hydrochloride is one of the most important varieties under research.